At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 33 enrolled
Drug / intervention
LY2787106 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Safety Study of LY2787106 in Patients With Cancer and Anemia
In Brief
A Phase 1 clinical trial evaluating LY2787106 and Iron Supplementation for Anemia. Completed, enrolled 33 participants across 9 sites.
Detailed Summary
This study will evaluate the safety LY2787106 in participants with cancer and anemia. It will also evaluate when LY2787106 can improve anemia. This study has two parts: Part A is a dose escalation evaluation. Part B is an evaluation of LY2787106 at a defined dose given with and without iron supplementation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2010
First PostedApr 2011
Primary CompletionDec 2014
TodayJul 2026
First PostedApr 25, 2011
Enrollment StartJan 1, 2010
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 15.2 years ago
Interventions
LY2787106drug
Administered IV.
Iron Supplementationdietary
Administered orally.